Open access · CC-BY
via OpenAlex
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
Tim F. Greten, Alejandro Forner, Firouzeh Korangy, G. Nkontchou, Nathalie Barget, Carmen Ayuso, Lars A. Ormandy, Michael P. Manns, Michel Beaugrand, Jordi Bruix
BMC Cancer · 2010 · ▲ 207 citations
Abstract
BACKGROUND: The sole effective option for patients with advanced HCC is sorafenib and there is an urgent need to develop new therapeutic approaches. Immunotherapy is a promising option that deserves major investigation. In this open label, single arm clinical trial, we analyzed the effect of a low dose cyclophosphamide treatment in combination with a telomerase peptide (GV1001) vaccination in patients with advanced HCC. METHODS: 40 patients with advanced HCC were treated with 300 mg/m2 cyclophosphamide on day -3 followed by GM-CSF + GV1001 vaccinations on days 1, 3, 5, 8, 15, 22, 36 followed by 4-weekly injections. Primary endpoint of this phase II trial was tumor response; secondary endpoints evaluated were TTP, TTSP, PFS, OS, safety and immune responses. RESULTS: None of the patients had a complete or partial response to treatment, 17 patients (45.9%) demonstrated a stable disease six months after initiation of treatment. The median TTP was 57.0 days; the median TTSP was estimated to be 358.0 days. Cyclophosphamide, GV1001 and GM-CSF treatment were well tolerated and most adverse events, which were of grade 1 or 2, were generally related to the injection procedure and injection site reactions. GV1001 treatment resulted in a decrease in CD4+CD25+Foxp3+ regulatory T cells; however, no GV1001 specific immune responses were detected after vaccination. CONCLUSIONS: Low dose cyclophosphamide treatment followed by GV1001 vaccinations did not show antitumor efficacy as per tumor response and time to progression. Further studies are needed to analyze the effect of a combined chemo-immunotherapy to treat patients with HCC. TRIAL REGISTRATION: NCT00444782.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/1471-2407-10-209
- Canonical
- link ↗
- Fetched
- 2026-06-22 MST
Cite this
APA
Greten, T.F., Forner, A., Korangy, F., Nkontchou, G., Barget, N., Ayuso, C., Ormandy, L.A., Manns, M.P., Beaugrand, M., & Bruix, J. (2010). A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. <em>BMC Cancer</em>. https://doi.org/10.1186/1471-2407-10-209
Vancouver
Greten TF, Forner A, Korangy F, Nkontchou G, Barget N, Ayuso C, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010. doi:10.1186/1471-2407-10-209.
BibTeX
@article{tim2010Aphase,
title = {A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma},
author = {Tim F. Greten and Alejandro Forner and Firouzeh Korangy and G. Nkontchou and Nathalie Barget and Carmen Ayuso and Lars A. Ormandy and Michael P. Manns and Michel Beaugrand and Jordi Bruix},
journal = {BMC Cancer},
year = {2010},
doi = {10.1186/1471-2407-10-209},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Longeveron Inc. 2014
Open access · US-GOV
A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty
British Journal of Cancer 2006
Open access · CC-BY
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
GuangZhou Cellgenes Biotechnology Co., Ltd. 2026
Open access · US-GOV
An Early Exploratory Clinical Trial to Evaluate CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia
Newcastle University ePrints (Newcastle Univesity) 2023
Preprint · CC-BY
Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction Randomized Pilot Trial
The Hong Kong Polytechnic University 2024
Open access · US-GOV
Smart Taiko-Drum Playing for Older Adults With Cognitive Frailty for Improving Cognitive and Physical Functions: A Randomized Controlled Feasibility Study
Prof. Dr. Clemens Schmitt 2017
Open access · US-GOV